Comparative Pharmacology
Head-to-head clinical analysis: CELONTIN versus EPRONTIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CELONTIN versus EPRONTIA.
CELONTIN vs EPRONTIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases levels of gamma-aminobutyric acid (GABA) in the central nervous system, possibly by inhibiting GABA transaminase or enhancing GABA release; also reduces calcium influx into neurons, stabilizing neuronal membranes.
Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity in the CNS by inhibiting presynaptic serotonin reuptake.
300 mg orally three times daily, increased by 300 mg every 3-4 days as tolerated; usual maintenance dose 900-2400 mg/day in divided doses.
Adults: 200-800 mg twice daily orally, starting at 200 mg twice daily, increasing by 200 mg/day weekly to maintenance.
None Documented
None Documented
Terminal elimination half-life: 40-60 hours in adults, 30-45 hours in children; prolonged liver disease or renal impairment may increase half-life.
Terminal elimination half-life is 20–30 hours in adults with normal renal function; prolonged to 40–60 hours in moderate to severe renal impairment (CrCl <50 mL/min), requiring dose adjustment.
Renal: approximately 40-60% as unchanged drug; hepatic metabolism accounts for the remainder, with metabolites excreted renally.
Renal excretion of unchanged drug accounts for approximately 70% of elimination, with 30% metabolized hepatically; metabolites are also renally excreted. Fecal elimination is minimal (<5%).
Category C
Category C
Anticonvulsant
Anticonvulsant